FDA rejects Amarin appeal on Vascepa trial design, shares slump

(Reuters) – Amarin Corp Plc’s shares fell more than 26 percent after U.S. health regulators rejected a preset testing process that was critical to the company seeking broader use of its blood…

    

Leave a Reply

Your email address will not be published.